[HTML][HTML] Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options

CC Sheu, YT Chang, SY Lin, YH Chen… - Frontiers in …, 2019 - frontiersin.org
Carbapenems are considered as last-resort antibiotics for the treatment of infections caused
by multidrug-resistant Gram-negative bacteria. With the increasing use of carbapenems in …

Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae

J Rodríguez-Baño, B Gutiérrez-Gutiérrez… - Clinical microbiology …, 2018 - Am Soc Microbiol
Therapy of invasive infections due to multidrug-resistant Enterobacteriaceae (MDR-E) is
challenging, and some of the few active drugs are not available in many countries. For …

[HTML][HTML] European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram …

M Paul, E Carrara, P Retamar, T Tängdén… - Clinical Microbiology …, 2022 - Elsevier
Scope These ESCMID guidelines address the targeted antibiotic treatment of third-
generation cephalosporin-resistant Enterobacterales (3GCephRE) and carbapenem …

[HTML][HTML] Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae

M Falcone, M Bassetti, G Tiseo, C Giordano, E Nencini… - Critical Care, 2020 - Springer
Abstract Background Bloodstream infections (BSIs) by Klebsiella pneumoniae
carbapenemase (KPC)-producing Klebsiella pneumoniae (Kp) are associated with high …

[HTML][HTML] Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli

M Zeng, J Xia, Z Zong, Y Shi, Y Ni, F Hu, Y Chen… - Journal of Microbiology …, 2023 - Elsevier
The dissemination of carbapenem-resistant Gram-negative bacilli (CRGNB) is a global
public health issue. CRGNB isolates are usually extensively drug-resistant or pandrug …

[HTML][HTML] Management of KPC-producing Klebsiella pneumoniae infections

M Bassetti, DR Giacobbe, H Giamarellou… - Clinical Microbiology …, 2018 - Elsevier
Background Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-
KP) has become one of the most important contemporary pathogens, especially in endemic …

Evolutionary trajectories toward ceftazidime-avibactam resistance in Klebsiella pneumoniae clinical isolates

A Carattoli, G Arcari, G Bibbolino, F Sacco… - Antimicrobial Agents …, 2021 - Am Soc Microbiol
ABSTRACT From January 2019 to April 2020, 32 KPC-producing, ceftazidime-avibactam
(CZA)-resistant Klebsiella pneumoniae strains were isolated in a university hospital in …

Synergistic activity of colistin-containing combinations against colistin-resistant Enterobacteriaceae

T Brennan-Krohn, A Pironti, JE Kirby - Antimicrobial agents and …, 2018 - Am Soc Microbiol
Resistance to colistin, a polypeptide drug used as an agent of last resort for the treatment of
infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram …

Risks of Infection and Mortality Among Patients Colonized With Klebsiella pneumoniae Carbapenemase–Producing K. pneumoniae: Validation of Scores and …

A Cano, B Gutiérrez-Gutiérrez, I Machuca… - Clinical Infectious …, 2018 - academic.oup.com
Background The management and indication of empiric treatment in Klebsiella pneumoniae
carbapenemase–producing K. pneumoniae (KPC-Kp)–colonized patients should be …

[HTML][HTML] Clinical impact of COVID-19 on multi-drug-resistant gram-negative bacilli bloodstream infections in an intensive care unit setting: two pandemics compared

F Cogliati Dezza, G Arcari, F Alessi, S Valeri, A Curtolo… - Antibiotics, 2022 - mdpi.com
Two mutually related pandemics are ongoing worldwide: the COVID-19 and antimicrobial
resistance pandemics. This study aims to evaluate the impact of COVID-19 on multi-drug …